Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439759 | 0.81 | TDP1 (0.46) | TDP1CYP1A2CYP2C19NPC1CYP3A4 | |
| SCHEMBL11211441 | 0.76 | MAPT (0.55) | TDP1MAPTCYP1A2CYP2C19NPC1 | |
| SCHEMBL31439900 | 0.75 | TDP1 (0.46) | TDP1MAPTCYP1A2CYP2C19L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11208518 | 0.75 | MAPT (0.54) | TDP1MAPTCYP1A2CYP2C19NPC1 | |
| SCHEMBL31439980 | 0.73 | TDP1 (0.43) | TDP1CYP1A2CYP2C19L3MBTL1MEN1 | |
| SCHEMBL31439835 | 0.72 | TDP1 (0.49) | TDP1CYP1A2CYP2C19L3MBTL1MEN1 | |
| SCHEMBL27625407 | 0.72 | GABRP (0.38) | MAPTSMN1; SMN2TLR8 | |
| SCHEMBL31281939 | 0.72 | TDP1 (0.59) | TDP1MAPTSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL18396500 | 0.72 | TDP1 (0.59) | TDP1MAPTSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL31439804 | 0.71 | ALDH1A1 (0.45) | CYP1A2CYP2C19RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | TDP1 2890/4885MAPT 2914/4885CYP1A2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.